Patents by Inventor Michal PYZIK

Michal PYZIK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods to manipulate alpha-fetoprotein (AFP)
    Patent number: 12110333
    Abstract: As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: October 8, 2024
    Inventors: Richard S. Blumberg, Kristi Baker, Michal Pyzik, Amit Gandhi
  • THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
    Publication number: 20210139582
    Abstract: The technology described herein is directed to immunotherapy agents for autoimmune disease, cancer, or allergy. In some embodiments, the immunotherapy agent comprises a bispecific antibody construct that specifically binds FcRn and a Type I or Type II Fc? T receptor. In some embodiments the bispecific antibody construct is a DvD-Ig construct. Also described herein are methods for treating autoimmune disease, cancer, or allergy, comprising administering an effective amount of a bispecific antibody construct to patient in need thereof.
    Type: Application
    Filed: February 13, 2019
    Publication date: May 13, 2021
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Michal PYZIK, Jonathan HUBBARD, Amit GANDHI
  • METHODS TO MANIPULATE ALPHA-FETOPROTEIN (AFP)
    Publication number: 20200031928
    Abstract: As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.
    Type: Application
    Filed: October 1, 2019
    Publication date: January 30, 2020
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Kristi BAKER, Michal PYZIK, Amit GANDHI
  • METHODS TO MANIPULATE ALPHA-FETOPROTEIN (AFP)
    Publication number: 20200010543
    Abstract: As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.
    Type: Application
    Filed: February 25, 2019
    Publication date: January 9, 2020
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Kristi BAKER, Michal PYZIK, Amit GANDHI
  • BLOCKADE OF ALPHAFETOPROTEIN (AFP) INTERACTIONS WITH BETA2-MICROGLOBULIN ASSOCIATED MOLECULES
    Publication number: 20190201496
    Abstract: Provided herein, in some aspects, are compositions and methods to inhibit AFP interactions with ?2M and/or Class I-related molecule interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate AFP interactions with ?2M and/or Class I-related molecule in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels is desired to increase immunosuppression or enhance organ regeneration.
    Type: Application
    Filed: September 14, 2017
    Publication date: July 4, 2019
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., UNIVERSITY OF OSLO
    Inventors: Richard S. BLUMBERG, Michal PYZIK, Amit GANDHI, Inger SANDLIE, Kine Marita Knudsen SAND, Jan Terje ANDERSEN
  • METHODS TO MANIPULATE ALPHA-FETOPROTEIN (AFP)
    Publication number: 20170044257
    Abstract: As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 16, 2017
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Kristi BAKER, Michal PYZIK, Amit GANDHI